BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Thursday reported a loss of $21 million in its third quarter.
The Berkeley, California-based company said it had a loss of 26 cents per share.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.
The drug developer posted revenue of $4.8 million in the period, exceeding Street forecasts. Four analysts surveyed by Zacks expected $4.6 million.
In the final minutes of trading on Thursday, the company's shares hit $1.07. A year ago, they were trading at $4.25.